NextCure IncNASDAQ:NXTC
- LAST PRICE1.3000
- TODAY'S CHANGE (%)-0.0100 (-0.7634%)
- Bid / Lots1.3000/ 109
- Ask / Lots1.3200/ 1
- Open / Previous Close1.3477 / 1.3100
- Day Range
- 52 Week Range
- Volume3,703
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NXTC |
|---|---|---|
| 09:39 ET | 100 | 1.3477 |
| 11:41 ET | 1000 | 1.3 |
| 11:45 ET | 1000 | 1.3 |
| 01:02 ET | 1000 | 1.32 |
| 01:06 ET | 100 | 1.3 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NextCure Inc | 36.6M | -0.6x | --- |
Passage Bio Inc | 37.3M | -0.5x | --- |
HST Global Inc | 35.7M | -43.6x | --- |
Lantern Pharma Inc | 35.3M | -2.0x | --- |
Surrozen Inc | 38.1M | -0.5x | --- |
Aeon Biopharma Inc | 34.7M | -0.1x | --- |
Company Information
NextCure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including Antibody-Drug Conjugates (ADCs), antibodies, and proteins. The Company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidates include NC410 and LNCB74. Its Clinical Oncology Programs are NC525 and NC318. Its Pre-Clinical Non-Oncology Programs are NC605 and NC181. NC410 is a LAIR-2 fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers. NCB74 is an ADC that is directed to B7-H4, a clinically validated cancer target.
Contact Information
- Headquarters
- 9000 Virginia Manor Rd Ste 200BELTSVILLE, MD, United States 20705-4214
- Phone
- 240-399-4900
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- David Kabakoff
- President, Chief Executive Officer, Director
- Michael Richman
- Chief Financial Officer
- Steven Cobourn
- Chief Operating Officer
- Timothy Mayer
- Senior Vice President, General Counsel
- Kevin Shaw
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $36.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 28.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.66 |
EPS | $-2.20 |
Book Value | $4.10 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
